The End Brain Cancer Initiative (EBCI), www.EndBrainCancer.org, is thrilled to announce expansion of their mission as it relates to increased patient disease education/awareness/outreach & access to advanced treatment options, diagnostics and clinical trials, including Next Generation Sequencing (NGS) as the organization partners with Endeavor BioMedicines, to advance these efforts on behalf of patients"

The Endeavor Story

With advances in next-generation sequencing and molecular profiling, we now have the tools to uncover the genetic culprits of disease. We can go after targets and indications we were not scientifically capable of investigating in the past. And we can finally bring patients best-in-class medicines across a spectrum of indications that target the core drivers of disease – making a significant impact even in terminal conditions.

At Endeavor BioMedicines, they are pursuing novel science and developing precision medicines. They combine advancements in technology with insights into the causes of disease to develop best-in-class medicines with the potential to treat the most severe health conditions, including cancer and fibrosis. 

Scan the QR code or click on it to learn more about ENV-101 for PTCH-1 LOF cancer treatment.